LadRx (LADX) Short Interest

View and export this data going back to 1986. Start your Free Trial

What is LadRx Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of LadRx's Short Interest

For the Biotechnology subindustry, LadRx's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

LadRx's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LadRx's Short Interest distribution charts can be found below:

* The bar in red indicates where LadRx's Short Interest falls into.

LadRx (LADX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LadRx Corp (OTCPK:LADX) » Definitions » Short Interest

Comparable Companies

Traded in Other Exchanges

N/A

Address

11726 San Vicente Boulevard, Suite 650, Los Angeles, CA, USA, 90049

Website

https://www.ladrxcorp.com

LadRx Corp operates as a biopharmaceutical research and development company in the healthcare sector of the United States. It is focused on the discovery, research, and clinical development of novel anti-cancer drug candidates that employ novel linker technologies to enhance the accumulation and release of cytotoxic anti-cancer agents at the tumor. The company develops Aldoxorubicin, which is meant to cure soft tissue sarcoma, a kind of tumor. It also develops Arimoclomol which is in development in Niemann Pick disease Type C (NPC) and Gaucher disease.

Executives

Cary J Claiborne	director	3056 SENECA CHIEF TRAIL, ELLICOTT CITY MD 21042
Stephen Snowdy	officer: Chief Executive Officer	C/O CYTRX CORPORATION, 11726 SAN VICENTE BOULEVARD, SUITE 650, LOS ANGELES CA 90049
Jennifer K. Simpson	director	C/O DELCATH SYSTEMS, INC., 810 SEVENTH AVENUE, SUITE 3505, NEW YORK NY 10019
Eric Curtis	officer: Pres., Chief Operating Officer	ONE MAIN STREET, SUITE 800, CAMBRIDGE MA 02142
Felix Kratz	officer: Vice President Drug Discovery	11726 SAN VICENTE BLVD., SUITE 650, LOS ANGELES CA 90049
Joel K Caldwell	director	11726 SAN VICENTE BLVD., SUITE 650, LOS ANGELES CA 90049
Chawla Shanta M.d.	officer: Senior VP-Drug Development	11726 SAN VICENTE BLVD., SUITE 650, LOS ANGELES CA 90049
Earl W Brien	director	11726 SAN VICENTE BLVD, SUITE 650, LOS ANGELES CA 90049
Olivia C Ware	officer: Chief Commercial Officer	11726 SAN VICENTE BLVD, SUITE 650, LOS ANGELES CA 90049
Cheryl Cohen	director	C/O MEDIVATION, INC., 201 SPEAR ST., 3RD FLOOR, SAN FRANCISCO CA 94105
Eric Jay Selter	director	11726 SAN VICENTE BLVD., SUITE 650, LOS ANGELES CA 90049
Anita J Chawla	director	11726 SAN VICENTE BLVD., SUITE 650, LOS ANGELES CA 90049
Joseph Rubinfeld	director	C/O SUPERGEN INC, 4140 DUBLIN BLVD STE 200, DUBLIN CA 94568
Douglas Scott Wieland	officer: Sr VP - Drug Development	11726 SAN VICENTE BLVD., SUITE 650, LOS ANGELES CA 90049
Louis Ignarro	director	11726 SAN VICENTE BLVD, STE 650, LOS ANGELES CA 90049